Who
Nicholas A. Saccomano
President and CEO
Company insider
Files Form 4 as: President and CEO, OnKure Therapeutics; Cso, Array Biopharma.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $4.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Aug 2014
- Last trade
- 21 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 23 Sep 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $25987 at $2.97 | filing |
| 21 Sep 2026filed 23 Sep 2026 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $25887 at $2.97 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —542,232 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —542,232 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,359 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,359 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,359 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,359 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,485 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,485 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,449 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,449 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,898 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,898 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —542,232 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —542,232 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,485 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,485 | filing |
News
No headline names them, or the companies they trade most, lately.